Vor Biopharma
Clinical trials sponsored by Vor Biopharma, explained in plain language.
Vor Biopharma
VOR
NASDAQ
Develops engineered hematopoietic stem cell therapies for blood cancers.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for muscle weakness: drug trial targets myasthenia gravis Results expected May 2027 (estimated) May already have reported ↗ 🚀 Make-or-break